Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status Meeting Abstract
| Authors: | Rizvi, N.; Chaft, J.; Balmanoukian, A.; Goldberg, S. B.; Sanborn, R. E.; Steele, K. E.; Rebelatto, M. C.; Gu, Y.; Karakunnel, J. J.; Antonia, S. |
| Abstract Title: | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| Meeting Title: | 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC 2015) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 3 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2015 Nov 4-8 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2015-11-04 |
| Language: | English |
| DOI: | 10.1186/2051-1426-3-S2-P193 |
| PROVIDER: | manual |
| PMCID: | PMC4649434 |
| Notes: | Meeting Abstract: P193 |
